These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 19319678)

  • 41. Canavan disease. Analysis of the nature of the metabolic lesions responsible for development of the observed clinical symptoms.
    Baslow MH; Resnik TR
    J Mol Neurosci; 1997 Oct; 9(2):109-25. PubMed ID: 9407392
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dietary triheptanoin rescues oligodendrocyte loss, dysmyelination and motor function in the nur7 mouse model of Canavan disease.
    Francis JS; Markov V; Leone P
    J Inherit Metab Dis; 2014 May; 37(3):369-81. PubMed ID: 24288037
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Astroglial redistribution of aquaporin 4 during spongy degeneration in a Canavan disease mouse model.
    Clarner T; Wieczorek N; Krauspe B; Jansen K; Beyer C; Kipp M
    J Mol Neurosci; 2014 May; 53(1):22-30. PubMed ID: 24272958
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Renewal of oligodendrocyte lineage reverses dysmyelination and CNS neurodegeneration through corrected N-acetylaspartate metabolism.
    Lotun A; Li D; Xu H; Su Q; Tuncer S; Sanmiguel J; Mooney M; Baer CE; Ulbrich R; Eyles SJ; Strittmatter L; Hayward LJ; Gessler DJ; Gao G
    Prog Neurobiol; 2023 Jul; 226():102460. PubMed ID: 37149081
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Aspartoacylase deficiency does not affect N-acetylaspartylglutamate level or glutamate carboxypeptidase II activity in the knockout mouse brain.
    Surendran S; Ezell EL; Quast MJ; Wei J; Tyring SK; Michals-Matalon K; Matalon R
    Brain Res; 2004 Aug; 1016(2):268-71. PubMed ID: 15246864
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The effect of N-acetyl-aspartyl-glutamate and N-acetyl-aspartate on white matter oligodendrocytes.
    Kolodziejczyk K; Hamilton NB; Wade A; Káradóttir R; Attwell D
    Brain; 2009 Jun; 132(Pt 6):1496-508. PubMed ID: 19383832
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Aspartoacylase supports oxidative energy metabolism during myelination.
    Francis JS; Strande L; Markov V; Leone P
    J Cereb Blood Flow Metab; 2012 Sep; 32(9):1725-36. PubMed ID: 22617649
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Loss of central auditory processing in a mouse model of Canavan disease.
    von Jonquieres G; Froud KE; Klugmann CB; Wong AC; Housley GD; Klugmann M
    PLoS One; 2014; 9(5):e97374. PubMed ID: 24826990
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunohistochemical localization of aspartoacylase in the rat central nervous system.
    Madhavarao CN; Moffett JR; Moore RA; Viola RE; Namboodiri MA; Jacobowitz DM
    J Comp Neurol; 2004 May; 472(3):318-29. PubMed ID: 15065127
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain.
    Janson C; McPhee S; Bilaniuk L; Haselgrove J; Testaiuti M; Freese A; Wang DJ; Shera D; Hurh P; Rupin J; Saslow E; Goldfarb O; Goldberg M; Larijani G; Sharrar W; Liouterman L; Camp A; Kolodny E; Samulski J; Leone P
    Hum Gene Ther; 2002 Jul; 13(11):1391-412. PubMed ID: 12162821
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A novel aspartoacylase (ASPA) gene mutation in Canavan disease.
    Durmaz AA; Akin H; Onay H; Vahabi A; Ozkinay F
    Fetal Pediatr Pathol; 2012 Aug; 31(4):236-9. PubMed ID: 22468686
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Atypical MRI findings in Canavan disease: a patient with a mild course.
    Yalcinkaya C; Benbir G; Salomons GS; Karaarslan E; Rolland MO; Jakobs C; van der Knaap MS
    Neuropediatrics; 2005 Oct; 36(5):336-9. PubMed ID: 16217711
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A new mouse model of Canavan leukodystrophy displays hearing impairment due to central nervous system dysmyelination.
    Carpinelli MR; Voss AK; Manning MG; Perera AA; Cooray AA; Kile BT; Burt RA
    Dis Model Mech; 2014 Jun; 7(6):649-57. PubMed ID: 24682784
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of AAV-2-mediated aspartoacylase gene transfer in the tremor rat model of Canavan disease.
    McPhee SW; Francis J; Janson CG; Serikawa T; Hyland K; Ong EO; Raghavan SS; Freese A; Leone P
    Brain Res Mol Brain Res; 2005 Apr; 135(1-2):112-21. PubMed ID: 15857674
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Metabolic acetate therapy improves phenotype in the tremor rat model of Canavan disease.
    Arun P; Madhavarao CN; Moffett JR; Hamilton K; Grunberg NE; Ariyannur PS; Gahl WA; Anikster Y; Mog S; Hallows WC; Denu JM; Namboodiri AM
    J Inherit Metab Dis; 2010 Jun; 33(3):195-210. PubMed ID: 20464498
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Non-genetic therapeutic approaches to Canavan disease.
    Roscoe RB; Elliott C; Zarros A; Baillie GS
    J Neurol Sci; 2016 Jul; 366():116-124. PubMed ID: 27288788
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Relationship between enzyme properties and disease progression in Canavan disease.
    Zano S; Wijayasinghe YS; Malik R; Smith J; Viola RE
    J Inherit Metab Dis; 2013 Jan; 36(1):1-6. PubMed ID: 22850825
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evidence supporting a role for N-acetyl-L-aspartate as a molecular water pump in myelinated neurons in the central nervous system. An analytical review.
    Baslow MH
    Neurochem Int; 2002 Apr; 40(4):295-300. PubMed ID: 11792458
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Aspartoacylase is restricted primarily to myelin synthesizing cells in the CNS: therapeutic implications for Canavan disease.
    Kirmani BF; Jacobowitz DM; Kallarakal AT; Namboodiri MA
    Brain Res Mol Brain Res; 2002 Nov; 107(2):176-82. PubMed ID: 12487123
    [TBL] [Abstract][Full Text] [Related]  

  • 60. N-acetylaspartate in the vertebrate brain: metabolism and function.
    Baslow MH
    Neurochem Res; 2003 Jun; 28(6):941-53. PubMed ID: 12718449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.